IBA takes next step in China deal
Proton therapy developer Ion Beam Applications (IBA) has taken a down payment...Read more on AuntMinnie.comRelated Reading: IBA to install carbon therapy in France IBA posts revenue increase in 1st half of 2019 IBA inks deal to install cyclotron in South Korea IBA takes order from Kan. NorthStar to buy IBA accelerators for Mo-99 production
The outcome of chordoma patients with local or distant failure after proton therapy is not well established. We assessed the disease-specific (DSS) and overall survival of patients recurring after proton therapy and evaluated the prognostic factors affecting DSS.
CONCLUSIONS: This work demonstrated the feasibility of using sCT generated with a GAN-based deep learning method for MRI-only treatment planning of patients with brain tumor in intensity-modulated proton therapy. PMID: 32216098 [PubMed - as supplied by publisher]
No abstract available
Abstract Positron emission tomography and prompt gamma detection are promising proton therapy monitoring modalities. Fast calculation of the expected distributions is desirable for comparison to measurements and to develop/train algorithms for automatic treatment error detection. A filtering formalism was used for positron-emitter predictions and adapted to allow for its use for the beamline of any proton therapy centre. A novel approach based on a filtering formalism was developed for the prediction of energy-resolved prompt-gamma distributions for arbitrary tissues. The method estimates prompt-gamma yields and t...
PALO ALTO, Calif., March 17, 2020 -- (Healthcare Sales &Marketing Network) -- Varian (NYSE: VAR) announced today, Proton International at UAB has now treated its first cancer patient with the Varian ProBeam® Compact proton therapy system. The center,... Devices, Oncology Varian Medical Systems, ProBeam, proton therapy, radiotherapy
Radiation therapy (RT) of thoracic cancers may cause severe radiation dermatitis (RD), which impacts on the quality of a patient's life. Aim of this study was to analyze the incidence of acute RD and develop normal tissue complication probability (NTCP) models for severe RD in thoracic cancer patients treated with Intensity-Modulated RT (IMRT) or Passive Scattering Proton Therapy (PSPT). We analyzed 166 Non-Small-Cell Lung Cancer (NSCLC) patients prospectively treated at a single institution with IMRT (103 patients) or PSPT (63 patients). All patients were treated to a prescribed dose of 60 to 74 Gy in conventional daily f...
This study evaluated the measurements of proton pencil beam scanning delivery made with a 2D ion chamber array in solid water on a 1D motion platform, where respiratory motion was simulated using sine and cosine4 waves representing sinusoidal symmetric and realistic asymmetric breathing motions, respectively. Motion amplitudes were 0.5 cm and 1 cm corresponding to 1 cm and 2 cm of maximum respiratory excursions, respectively, with 5 sec fixed breathing cycle. The treatment plans were created to mimic spherical targets of 3 cm or 10 cm diameter located at 5 cm or 1 cm depth in so...
To report control and toxicity outcomes for patients with adenoid cystic carcinoma (ACC) of the non-skull base head and neck treated at a single institution with proton therapy.
We report our dosimetric and clinical outcomes in terms of disease control and toxicity in patients with parotid gland malignancies treated with IMPT.
To assess the outcomes and toxicities for squamous cell carcinoma (SCC) of the larynx treated with proton therapy.